Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-10-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle raised funds for cash management, including details of financial products purchased, redeemed, and related risk controls. It is a regulatory announcement about financing activities, specifically the use of idle raised funds for cash management and investment in low-risk financial products. The document is relatively short (4317 characters) and does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a proxy, voting result, or management change announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital management.
2019-10-23 Chinese
第二届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board meeting resolution of Xiamen Aide Biomedical Technology Co., Ltd. It specifically states that the supervisory board reviewed and approved the company's 2019 third quarter report. The document includes details about the meeting date, attendance, and voting results. However, the document itself is not the quarterly report but an announcement of the supervisory board's approval of that report. The document length is short (672 characters), and it serves as a formal disclosure rather than containing substantive financial data or the full report. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement related to the approval of a quarterly report, not the report itself.
2019-10-21 Chinese
第二届董事会第十次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the board of directors meeting resolution, specifically the approval of the 2019 third quarter report. It states the meeting details, voting results, and references the full quarterly report being available on the official disclosure website and in newspapers. The document itself does not contain the full quarterly financial statements or substantive financial data, but rather announces the approval and availability of the report elsewhere. The document length is short (732 characters), consistent with an announcement rather than the full report. Therefore, this is a Declaration of Voting Results & Voting Rights Announcement (DVA) related to the approval of the quarterly report.
2019-10-21 Chinese
2019年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 Third Quarter Report" of 厦门艾德生物医药科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2019
2019-10-21 Chinese
关于2019年第三季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (339 characters) stating that the full 2019 third quarter report has been disclosed on the official stock exchange website. It does not contain the actual financial data or substantive analysis but merely informs investors about the availability of the report. According to the 'MENU VS MEAL' rule, such a brief notice that points to the report's publication is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2019-10-21 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 厦门艾德生物医药科技股份有限公司 (Amoy Diagnostics Co., LTD). It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, share issuance, share transfer, shareholder meetings, and other governance-related rules. It references relevant laws such as the Company Law and Securities Law of China. The content is legal and governance-focused, detailing internal rules and procedures rather than financial results, audit opinions, or meeting announcements. It is not a report of financial performance, nor an announcement or transcript. It is a governance document outlining the company's internal rules and board structure. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2019-10-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.